MedTrace Logo

IGF-1, Sarcopenia and Mortality: a Cohort Study in Patient With Cognitive Impairment

NCT02139410 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 589

Last updated 2014-05-15

No results posted yet for this study

Summary

Insulin-like growth factor 1 (IGF)-1 is an important neuromyotrophic hormone. Disregulation of this hormone has been reported to influence the genesis of cognitive impairment and dementia in the elderly patients. We analyzed the possible link between IGF-1 and risk of Sarcopenia and Mortality in a cohort of elder patients with cognitive impairment.

Conditions

Interventions

PROCEDURE

IGF-1 serum value

Evaluation of IGF-1 serum value at baseline, 24 and 48 months

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Vincenzo Gianturco, MD · University of Roma La Sapienza

Eligibility

Min Age
65 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2013-09-30
Completion
2013-11-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02139410 on ClinicalTrials.gov